Poland· PL-100354002

Odomzo

A sonidegib product containing sonidegibum, registered in Poland by Sun Pharmaceutical Industries Europe B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC L01XJ02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedOdomzoATCL01XJ02REGISTER NO.PL-100354002PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Sonidegib is registered in 11 of 19 countries.

Countries holding a registration under ATC L01XJ02 (sonidegib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Sonidegib · ATC L01XJ02

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of sonidegib costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Sonidegib · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • CH Switzerland$224.10
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Sonidegibum
Manufacturer
Sun Pharmaceutical Industries Europe B.V.
Country
Poland (PL)
ATC code
L01XJ02
ATC class
Sonidegib
Defined daily dose
0.2 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991239022
  • gtin
    05909991239039

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

172 interactions on record for sonidegib.

Graded by severity as the source publishes them — 82 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Sonidegib · interactions on record

172 records

  • 82 severe
  • 81 moderate
  • 9 minor

Most severe, free to view

  • ClotrimazoleA01AB18severe
  • AprepitantA04AD12severe
  • LonafarnibA16AX20severe
  • BerotralstatB06AC06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/1d0205a5-9a91-4cbc-aae1-df83fbb91585
GET /v1/drugs/1d0205a5-9a91-4cbc-aae1-df83fbb91585?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki twarde",
  "source": "urpl",
  "strength": "200 mg",
  "packaging": "05909991239022 ¦ Rpz ¦ EU/1/15/1030/001 ¦ 111035\n10 kaps.\n05909991239039 ¦ Rpz ¦ EU/1/15/1030/002 ¦ 111036\n30 kaps.",
  "substance": "Sonidegibum 200 mg",
  "common_name": "Sonidegibum",
  "pl_product_id": "100354002",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about sonidegib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.